MedTrace Logo

A 14-week, Multi-center Study of [S,S]-Reboxetine in Patients With Fibromyalgia.

NCT00612170 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1129

Last updated 2019-12-12

No results posted yet for this study

Summary

This is a study to investigate the effectiveness and safety of \[S,S\]-Reboxetine in relieving the symptoms of Fibromyalgia in patients. A previous study demonstrated clinically meaningful treatment effects in fibromyalgia, based on pain and functional endpoints.

Conditions

  • Fibromyalgia

Interventions

DRUG

[S,S]-Reboxetine

10 mg oral tablet once a day dosing

DRUG

Placebo

0 mg oral tablet once a day dosing

DRUG

[S,S]-Reboxetine

4 mg oral tablet once a day dosing

DRUG

[S,S]-Reboxetine

8 mg oral tablet once a day dosing

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00612170 on ClinicalTrials.gov